Finance
By: Shree1news, 17 MAY 2021
New Delhi: The first batch of DRDO-developed anti-Covid drug 2-DG (2-deoxy-D-glucose) was launched on Monday to treat patients suffering from the deadly disease. The medicine comes in powder form and can be taken with water.
Defence Minister Rajnath Singh and Health Minister Harsh Vardhan released the first batch of the 2-DG, an anti-Covid-19 therapeutic application of the drug developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO) in collaboration with Dr Reddy’s Laboratories (DRL).
Rajnath Singh handed over the anti-Covid drug to his cabinet colleague Harsh Vardhan who handed over it to Delhi All India Institute of Medical Sciences (AIIMS) director Randeep Guleria at an event here.
The Defence Minister would be later distributing around 10,000 doses of the drug to a few hospitals within the national capital.
The Drugs Controller General of India (DCGI) granted emergency use nod for the drug last week. The drug could be a game-changer in the battle against pandemic because it helps in faster recovery of hospitalised patients and reduces oxygen dependence.
Clinical trial results have shown that the drug helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in Covid patients.
The medicine was found to be safe for Covid-19 patients in phase 2 trials, conducted between May and October last year. It was found to be efficient in reducing short the hospital stays of Covid sufferers and lowering their supplemental oxygen dependence.
Throughout the first wave of the pandemic in April last year, INMAS-DRDO scientists conducted laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad, and found that this molecule works successfully against SARS-CoV-2 virus and inhibits the viral growth.
Based mostly on these results, the Drugs Controller General of India (DCGI) Central Drugs Standard Control Organisation (CDSCO) permitted Phase-II medical trial of 2- DG in Covid-19 patients in May 2020. The DRDO, together with its industry partner DRL, Hyderabad, started the medical trials to test the safety and efficacy of the drug in Covid-19 patients.
In Phase-II trials (including dose ranging) performed throughout May-October 2020, the drug was found to be safe in Covid-19 sufferers and showed significant improvement in their recovery. Phase-II was performed in six hospitals and Phase IIb (dose ranging) clinical trial was performed at 11 hospitals all over the nation. Phase-II trial was carried out on 110 patients.
Source:A-N
viist at : www.shree1news.com
